S&P 500   3,386.15 (+0.47%)
DOW   29,348.03 (+0.40%)
QQQ   236.98 (+0.96%)
AAPL   323.62 (+1.45%)
FB   217.49 (-0.14%)
MSFT   187.28 (+0.03%)
GOOGL   1,524.87 (+0.36%)
AMZN   2,170.22 (+0.67%)
CGC   21.77 (-0.77%)
NVDA   314.70 (+6.11%)
BABA   222.14 (+0.73%)
MU   59.99 (+3.88%)
GE   12.61 (-1.10%)
TSLA   917.42 (+6.88%)
AMD   58.90 (+3.53%)
T   38.44 (+0.47%)
ACB   1.71 (+4.27%)
F   8.00 (-0.74%)
NFLX   386.19 (-0.41%)
PRI   135.69 (+0.05%)
BAC   34.72 (+1.31%)
DIS   141.30 (+1.55%)
GILD   67.35 (+0.51%)
S&P 500   3,386.15 (+0.47%)
DOW   29,348.03 (+0.40%)
QQQ   236.98 (+0.96%)
AAPL   323.62 (+1.45%)
FB   217.49 (-0.14%)
MSFT   187.28 (+0.03%)
GOOGL   1,524.87 (+0.36%)
AMZN   2,170.22 (+0.67%)
CGC   21.77 (-0.77%)
NVDA   314.70 (+6.11%)
BABA   222.14 (+0.73%)
MU   59.99 (+3.88%)
GE   12.61 (-1.10%)
TSLA   917.42 (+6.88%)
AMD   58.90 (+3.53%)
T   38.44 (+0.47%)
ACB   1.71 (+4.27%)
F   8.00 (-0.74%)
NFLX   386.19 (-0.41%)
PRI   135.69 (+0.05%)
BAC   34.72 (+1.31%)
DIS   141.30 (+1.55%)
GILD   67.35 (+0.51%)
S&P 500   3,386.15 (+0.47%)
DOW   29,348.03 (+0.40%)
QQQ   236.98 (+0.96%)
AAPL   323.62 (+1.45%)
FB   217.49 (-0.14%)
MSFT   187.28 (+0.03%)
GOOGL   1,524.87 (+0.36%)
AMZN   2,170.22 (+0.67%)
CGC   21.77 (-0.77%)
NVDA   314.70 (+6.11%)
BABA   222.14 (+0.73%)
MU   59.99 (+3.88%)
GE   12.61 (-1.10%)
TSLA   917.42 (+6.88%)
AMD   58.90 (+3.53%)
T   38.44 (+0.47%)
ACB   1.71 (+4.27%)
F   8.00 (-0.74%)
NFLX   386.19 (-0.41%)
PRI   135.69 (+0.05%)
BAC   34.72 (+1.31%)
DIS   141.30 (+1.55%)
GILD   67.35 (+0.51%)
S&P 500   3,386.15 (+0.47%)
DOW   29,348.03 (+0.40%)
QQQ   236.98 (+0.96%)
AAPL   323.62 (+1.45%)
FB   217.49 (-0.14%)
MSFT   187.28 (+0.03%)
GOOGL   1,524.87 (+0.36%)
AMZN   2,170.22 (+0.67%)
CGC   21.77 (-0.77%)
NVDA   314.70 (+6.11%)
BABA   222.14 (+0.73%)
MU   59.99 (+3.88%)
GE   12.61 (-1.10%)
TSLA   917.42 (+6.88%)
AMD   58.90 (+3.53%)
T   38.44 (+0.47%)
ACB   1.71 (+4.27%)
F   8.00 (-0.74%)
NFLX   386.19 (-0.41%)
PRI   135.69 (+0.05%)
BAC   34.72 (+1.31%)
DIS   141.30 (+1.55%)
GILD   67.35 (+0.51%)
Log in

NASDAQ:FLDM - Fluidigm Stock Price, Forecast & News

$3.78
+0.22 (+6.18 %)
(As of 02/19/2020 04:00 PM ET)
Today's Range
$3.62
Now: $3.78
$3.94
50-Day Range
$3.31
MA: $3.77
$4.35
52-Week Range
$2.12
Now: $3.78
$14.90
Volume967,713 shs
Average Volume802,514 shs
Market Capitalization$262.96 million
P/E RatioN/A
Dividend YieldN/A
Beta2.34
Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research in the United States and Europe. It offers analytical systems comprising Helios, a CyTOF system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents and Maxpar human immune monitoring panel kit and workflow. Read More…

Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryLife Sciences Tools & Services
SectorMedical
Current SymbolNASDAQ:FLDM
CUSIP34385P10
Phone650-266-6000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$117.24 million
Book Value$1.46 per share

Profitability

Net Income$-64,790,000.00

Miscellaneous

Employees535
Market Cap$262.96 million
Next Earnings Date5/7/2020 (Estimated)
OptionableOptionable

Receive FLDM News and Ratings via Email

Sign-up to receive the latest news and ratings for FLDM and its competitors with MarketBeat's FREE daily newsletter.


Fluidigm (NASDAQ:FLDM) Frequently Asked Questions

What is Fluidigm's stock symbol?

Fluidigm trades on the NASDAQ under the ticker symbol "FLDM."

How were Fluidigm's earnings last quarter?

Fluidigm Co. (NASDAQ:FLDM) announced its earnings results on Monday, February, 10th. The medical research company reported ($0.18) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.13) by $0.05. The medical research company had revenue of $32.44 million for the quarter, compared to analyst estimates of $32.14 million. Fluidigm had a negative return on equity of 20.31% and a negative net margin of 55.26%. The business's revenue for the quarter was up .4% compared to the same quarter last year. View Fluidigm's Earnings History.

When is Fluidigm's next earnings date?

Fluidigm is scheduled to release their next quarterly earnings announcement on Thursday, May 7th 2020. View Earnings Estimates for Fluidigm.

What guidance has Fluidigm issued on next quarter's earnings?

Fluidigm updated its FY 2020 After-Hours earnings guidance on Monday, February, 10th. The company provided EPS guidance of for the period. The company issued revenue guidance of $126.622-130.14 million, compared to the consensus revenue estimate of $124.85 million.

What price target have analysts set for FLDM?

4 equities research analysts have issued 12-month price targets for Fluidigm's shares. Their forecasts range from $7.00 to $16.00. On average, they anticipate Fluidigm's share price to reach $11.75 in the next year. This suggests a possible upside of 210.8% from the stock's current price. View Analyst Price Targets for Fluidigm.

What is the consensus analysts' recommendation for Fluidigm?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fluidigm in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Fluidigm.

Has Fluidigm been receiving favorable news coverage?

Media headlines about FLDM stock have been trending somewhat negative recently, InfoTrie reports. InfoTrie scores the sentiment of news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Fluidigm earned a coverage optimism score of -1.4 on InfoTrie's scale. They also gave media headlines about the medical research company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Fluidigm.

Are investors shorting Fluidigm?

Fluidigm saw a increase in short interest in January. As of January 31st, there was short interest totalling 2,060,000 shares, an increase of 18.4% from the January 15th total of 1,740,000 shares. Based on an average daily trading volume, of 1,020,000 shares, the short-interest ratio is presently 2.0 days. Currently, 3.0% of the shares of the company are sold short. View Fluidigm's Current Options Chain.

Who are some of Fluidigm's key competitors?

What other stocks do shareholders of Fluidigm own?

Who are Fluidigm's key executives?

Fluidigm's management team includes the folowing people:
  • Mr. Stephen Christopher Linthwaite, Pres, CEO & Director (Age 46)
  • Mr. Vikram Jog, CFO & Principal Accounting Officer (Age 63)
  • Mr. Nicholas S. Khadder, Sr. VP, Gen. Counsel & Corp. Sec. (Age 45)
  • Ms. Mai Chan Yow, MD of Fluidigm Singapore Pte Ltd & EVP of Worldwide Manufacturing - Fluidigm Singapore Pte Ltd (Age 60)
  • Dr. Stephen R. Quake, Co-Founder & Chairman of Advisory Board

Who are Fluidigm's major shareholders?

Fluidigm's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Russell Investments Group Ltd. (8.42%), Levin Easterly Partners LLC (6.30%), Partner Fund Management L.P. (4.65%), Renaissance Technologies LLC (4.01%), Acadian Asset Management LLC (2.43%) and State Street Corp (2.03%). Company insiders that own Fluidigm stock include Levin Capital Strategies, LP, Levin Easterly Partners Llc, Nicolas Barthelemy, Samuel D Colella and Stephen Christopher Linthwaite. View Institutional Ownership Trends for Fluidigm.

Which institutional investors are selling Fluidigm stock?

FLDM stock was sold by a variety of institutional investors in the last quarter, including Levin Easterly Partners LLC, Schonfeld Strategic Advisors LLC, Goldman Sachs Group Inc., Cubist Systematic Strategies LLC, AQR Capital Management LLC, Cadence Capital Management LLC, New York State Common Retirement Fund and Bank of America Corp DE. Company insiders that have sold Fluidigm company stock in the last year include Levin Easterly Partners Llc and Nicolas Barthelemy. View Insider Buying and Selling for Fluidigm.

Which institutional investors are buying Fluidigm stock?

FLDM stock was bought by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Alyeska Investment Group L.P., Jacobs Levy Equity Management Inc., Acadian Asset Management LLC, Parkman Healthcare Partners LLC, Silverback Asset Management LLC, Dupont Capital Management Corp and Partner Fund Management L.P.. Company insiders that have bought Fluidigm stock in the last two years include Levin Capital Strategies, LP, Nicolas Barthelemy, Samuel D Colella and Stephen Christopher Linthwaite. View Insider Buying and Selling for Fluidigm.

How do I buy shares of Fluidigm?

Shares of FLDM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Fluidigm's stock price today?

One share of FLDM stock can currently be purchased for approximately $3.78.

How big of a company is Fluidigm?

Fluidigm has a market capitalization of $262.96 million and generates $117.24 million in revenue each year. The medical research company earns $-64,790,000.00 in net income (profit) each year or ($0.53) on an earnings per share basis. Fluidigm employs 535 workers across the globe.View Additional Information About Fluidigm.

What is Fluidigm's official website?

The official website for Fluidigm is http://www.fluidigm.com/.

How can I contact Fluidigm?

Fluidigm's mailing address is 7000 Shoreline Court Suite 100, South San Francisco CA, 94080. The medical research company can be reached via phone at 650-266-6000 or via email at [email protected]


MarketBeat Community Rating for Fluidigm (NASDAQ FLDM)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  495 (Vote Outperform)
Underperform Votes:  313 (Vote Underperform)
Total Votes:  808
MarketBeat's community ratings are surveys of what our community members think about Fluidigm and other stocks. Vote "Outperform" if you believe FLDM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FLDM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/19/2020 by MarketBeat.com Staff

Featured Article: Monthly Dividend Stocks

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel